Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel

Maciej Banach, Manfredi Rizzo, Peter P. Toth, Michel Farnier, Michael H. Davidson, Khalid Al-Rasadi, Wilbert S. Aronow, Vasilis Athyros, Dragan M. Djuric, Marat V. Ezhov, Robert S. Greenfield, G. Kees Hovingh, Karam Kostner, Corina Serban, Daniel Lighezan, Zlatko Fras, Patrick M. Moriarty, Paul Muntner, Assen Goudev, Richard Ceska & 11 others Stephen J. Nicholls, Marlena Broncel, Dragana Nikolic, Daniel Pella, Raman Puri, Jacek Rysz, Nathan D. Wong, Laszlo Bajnok, Steven R. Jones, Kausik K. Ray, Dimitri P. Mikhailidis

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15% of patients.In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented.

Original languageEnglish
Pages (from-to)935-955
Number of pages21
JournalExpert Opinion on Drug Safety
Volume14
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Lipids
Muscles
Therapeutics
Atherosclerosis
Cardiovascular Diseases

Keywords

  • Definition
  • Muscle symptoms
  • Risk factors
  • Statin intolerance

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel. / Banach, Maciej; Rizzo, Manfredi; Toth, Peter P.; Farnier, Michel; Davidson, Michael H.; Al-Rasadi, Khalid; Aronow, Wilbert S.; Athyros, Vasilis; Djuric, Dragan M.; Ezhov, Marat V.; Greenfield, Robert S.; Hovingh, G. Kees; Kostner, Karam; Serban, Corina; Lighezan, Daniel; Fras, Zlatko; Moriarty, Patrick M.; Muntner, Paul; Goudev, Assen; Ceska, Richard; Nicholls, Stephen J.; Broncel, Marlena; Nikolic, Dragana; Pella, Daniel; Puri, Raman; Rysz, Jacek; Wong, Nathan D.; Bajnok, Laszlo; Jones, Steven R.; Ray, Kausik K.; Mikhailidis, Dimitri P.

In: Expert Opinion on Drug Safety, Vol. 14, No. 6, 01.06.2015, p. 935-955.

Research output: Contribution to journalArticle

Banach, M, Rizzo, M, Toth, PP, Farnier, M, Davidson, MH, Al-Rasadi, K, Aronow, WS, Athyros, V, Djuric, DM, Ezhov, MV, Greenfield, RS, Hovingh, GK, Kostner, K, Serban, C, Lighezan, D, Fras, Z, Moriarty, PM, Muntner, P, Goudev, A, Ceska, R, Nicholls, SJ, Broncel, M, Nikolic, D, Pella, D, Puri, R, Rysz, J, Wong, ND, Bajnok, L, Jones, SR, Ray, KK & Mikhailidis, DP 2015, 'Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel', Expert Opinion on Drug Safety, vol. 14, no. 6, pp. 935-955. https://doi.org/10.1517/14740338.2015.1039980
Banach, Maciej ; Rizzo, Manfredi ; Toth, Peter P. ; Farnier, Michel ; Davidson, Michael H. ; Al-Rasadi, Khalid ; Aronow, Wilbert S. ; Athyros, Vasilis ; Djuric, Dragan M. ; Ezhov, Marat V. ; Greenfield, Robert S. ; Hovingh, G. Kees ; Kostner, Karam ; Serban, Corina ; Lighezan, Daniel ; Fras, Zlatko ; Moriarty, Patrick M. ; Muntner, Paul ; Goudev, Assen ; Ceska, Richard ; Nicholls, Stephen J. ; Broncel, Marlena ; Nikolic, Dragana ; Pella, Daniel ; Puri, Raman ; Rysz, Jacek ; Wong, Nathan D. ; Bajnok, Laszlo ; Jones, Steven R. ; Ray, Kausik K. ; Mikhailidis, Dimitri P. / Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel. In: Expert Opinion on Drug Safety. 2015 ; Vol. 14, No. 6. pp. 935-955.
@article{4959f3ac6ef3485d8eccc867aebd545c,
title = "Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel",
abstract = "Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15{\%} of patients.In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented.",
keywords = "Definition, Muscle symptoms, Risk factors, Statin intolerance",
author = "Maciej Banach and Manfredi Rizzo and Toth, {Peter P.} and Michel Farnier and Davidson, {Michael H.} and Khalid Al-Rasadi and Aronow, {Wilbert S.} and Vasilis Athyros and Djuric, {Dragan M.} and Ezhov, {Marat V.} and Greenfield, {Robert S.} and Hovingh, {G. Kees} and Karam Kostner and Corina Serban and Daniel Lighezan and Zlatko Fras and Moriarty, {Patrick M.} and Paul Muntner and Assen Goudev and Richard Ceska and Nicholls, {Stephen J.} and Marlena Broncel and Dragana Nikolic and Daniel Pella and Raman Puri and Jacek Rysz and Wong, {Nathan D.} and Laszlo Bajnok and Jones, {Steven R.} and Ray, {Kausik K.} and Mikhailidis, {Dimitri P.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1517/14740338.2015.1039980",
language = "English",
volume = "14",
pages = "935--955",
journal = "Expert Opinion on Drug Safety",
issn = "1474-0338",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Statin intolerance-an attempt at a unified definition. Position paper from an International Lipid Expert Panel

AU - Banach, Maciej

AU - Rizzo, Manfredi

AU - Toth, Peter P.

AU - Farnier, Michel

AU - Davidson, Michael H.

AU - Al-Rasadi, Khalid

AU - Aronow, Wilbert S.

AU - Athyros, Vasilis

AU - Djuric, Dragan M.

AU - Ezhov, Marat V.

AU - Greenfield, Robert S.

AU - Hovingh, G. Kees

AU - Kostner, Karam

AU - Serban, Corina

AU - Lighezan, Daniel

AU - Fras, Zlatko

AU - Moriarty, Patrick M.

AU - Muntner, Paul

AU - Goudev, Assen

AU - Ceska, Richard

AU - Nicholls, Stephen J.

AU - Broncel, Marlena

AU - Nikolic, Dragana

AU - Pella, Daniel

AU - Puri, Raman

AU - Rysz, Jacek

AU - Wong, Nathan D.

AU - Bajnok, Laszlo

AU - Jones, Steven R.

AU - Ray, Kausik K.

AU - Mikhailidis, Dimitri P.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15% of patients.In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented.

AB - Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10-15% of patients.In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented.

KW - Definition

KW - Muscle symptoms

KW - Risk factors

KW - Statin intolerance

UR - http://www.scopus.com/inward/record.url?scp=84929578095&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929578095&partnerID=8YFLogxK

U2 - 10.1517/14740338.2015.1039980

DO - 10.1517/14740338.2015.1039980

M3 - Article

VL - 14

SP - 935

EP - 955

JO - Expert Opinion on Drug Safety

JF - Expert Opinion on Drug Safety

SN - 1474-0338

IS - 6

ER -